ArticleFrontiers in public health2026
Analysis of the utilization and effectiveness of tuberculosis digital adherence technology in southeastern China.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In response to the World Health Organization's advocacy for patient-centered care, Fujian Province, China, initiated the promotion of Digital Adherence Technology (DAT) in 2024 as an optional strategy to enhance treatment adherence-a critical determinant of patient outcomes. This study aimed to evaluate the real-world implementation and effectiveness of this program. Methods: We conducted a multi-site study in four prefecture-level cities where DAT had been deployed to over 100 patients. Data were extracted from the national Tuberculosis Information Management System and linked with DAT platform records. Patients with DAT records were assigned to the DAT group, others to the conventional care group. We analyzed factors associated with DAT non-adoption. Adherence was compared between groups using three indicators: sputum smear examination rate at month two, smear conversion rate at month two (among bacteriologically confirmed patients), and loss to follow-up rate. Propensity score matching (PSM) was employed to balance baseline characteristics, followed by subgroup analyses. Results: The overall DAT utilization rate was 50.90%. Protective factors against DAT non-use included female sex (aOR = 0.829, 95% CI: 0.716-0.960), non-Han ethnicity (aOR = 0.555, 95% CI: 0.343-0.898), use of fixed-dose combination therapy (aOR = 0.806, 95% CI: 0.666-0.975), and concurrent extrapulmonary TB (aOR = 0.761, 95% CI: 0.642-0.902). Compared to Fuzhou, patients in Putian, Quanzhou, and Ningde had significantly lower odds of non-use (aORs: 0.024, 0.076, 0.030). Migrant status (aOR = 2.621, 95% CI: 2.144-3.203) and symptomatic presentation at diagnosis (aOR = 1.604, 95% CI: 1.401-1.836) were risk factors. The DAT group demonstrated a significantly higher month-two smear examination rate than the conventional group in both the full and PSM-matched cohorts ( Conclusion: DAT utilization in Fujian remains moderate and is influenced by specific demographic and clinical factors. While DAT can improve process adherence indicators, its impact on definitive treatment outcomes requires further investigation. Optimization of patient management should include formal integration of DAT, workflow streamlining, and personalized intervention strategies. Future research must develop and evaluate effective interventions for DAT-identified non-adherent patients to translate monitoring data into improved clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.